Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach





Meeting AMR One Health Network
21 September 2023

AMR – a priority since 2001

2001: Community Strategy against AMR

2011: Action plan against the rising threats from AMR

2017:EU One Health Action Plan against AMR

2019: Regulations on veterinary medicines and medicated feed

2020: Farm to Fork Strategy

2020: Pharmaceutical Strategy for Europe

2020: European Health Union

2022: <u>Veterinary Medicinal Products</u>

2022: Global Health Strategy

2023: Reform of the EU Pharmaceutical legislation

2023: Council Recommendation on stepping up EU actions to combat AMR in a One Health approach

WHY?

- Responsible for more than 35 000 deaths every year in the EU/EEA
- EUR 1.5 billion per year in healthcare costs and productivity losses in the EU
- Threatens food security and food safety
- Global estimation by 2050:
 - 10 million deaths globally each year
 - a reduction of 2% to 3.5% in global gross domestic product
 - up to USD 100 trillion costs to the world economy
 - We can only combat AMR by applying the One Health approach



One Health approach to AMR

- The One Health approach is based on the principle that human, animal and environment health are intrinsically linked.
- One Health can only be reached when joint efforts are taken in these three areas.
- The fight against AMR must address human, animal and environmental concerns in a comprehensive manner involving a wide range of actors.



Council Recommendation on AMR - preparation COM proposal

Stakeholder consultations: <u>call for evidence</u> from 24 February 2022 to 24 March 2022 **Collection and use of expertise**:

- Study on a future proofing analysis of the 2017 EU AMR Action Plan
- Feasibility study on stockpiling of antimicrobials against AMR
- Study on bringing AMR medical countermeasures to the market
- Opinion on "Managing antimicrobial resistance across the health system" from the independent expert panel on effective ways of investing in health
- Overview report on Member States' One Health National Action Plans against AMR
- ■Results of the 2022 Eurobarometer on AMR
- Report of the subgroup under the EU AMR One Health Network

Objectives of the Council Recommendation

Builds on and completes 2017 European Action Plan against AMR
Provide **recommendations to the Commission and to Member States** in order to maximize synergies and to attain a strong and effective response against AMR across the EU.

Strengthen One Health national action plans on AMR Reinforce surveillance and monitoring of AMR and antimicrobial consumption

Strengthen infection prevention and control

Strengthen
antimicrobial
stewardship and
prudent use of
antimicrobials

Recommend targets for AMR and antimicrobial consumption in human health

Improve
awareness,
education
and
training

Foster research & development, and incentives for innovation and access to antimicrobials and other AMR medical countermeasures

Increase cooperation

Enhance global actions

A. National Action Plans against AMR

National Action Plans based on the One Health approach in all Member States

- Regularly evaluated and updated
- Effective governance
- Measurable goals, implementation modalities and indicators
- Links with elements of the National Common Agricultural Policy Strategic Plans
- Environment dimension
- Human and financial resources
- Publicly available

B. Surveillance and monitoring of AMR and antimicrobial consumption (AMC)

- Close surveillance and monitoring gaps and ensure completeness of data in humans
 - At all levels (e.g. community, hospitals and long-term care facilities)
 - Surveillance extended to exposure to substances in the environment (plant protection products, biocidal products)
 - Data collection on antimicrobials consumption in humans
- Integrated AMR and AMC surveillance systems, encompassing human health, animal health, plant health, food, wastewater and the environment
- Assessment of animal diseases caused by bacteria resistant to antimicrobials

C. Infection prevention and control (IPC)

- IPC measures in human health: implemented and continuously monitored
 - Strengthened infection prevention and control in healthcare settings and longterm care facilities
 - Upgraded hospital infrastructures
 - Strong links to patient safety and prevention of healthcare associated infections
 - Continuous training
 - National immunisation programmes
- IPC measures for health and welfare of food-producing animals
- Good, evidence-based, manure management practices and good sewage sludge management practices
- EU infection prevention and control guidelines in human health

D. Antimicrobial stewardship and prudent use of antimicrobials

- Measures in human health to support the prudent use of antimicrobial agents
- Collection and safe disposal of antimicrobials on human and veterinary side
- **EU guidelines** for the treatment of major common infections and perioperative prophylaxis in humans
- Assessment of risk of development of resistance to human and veterinary antimicrobials from the use of plant protection products or biocidal products

E. Recommended targets for antimicrobial consumption and antimicrobial resistance

By 2030 (baseline year 2019):

- total consumption of antibiotics in humans to be reduced by 20% in the EU
- at least 65% total consumption of antibiotics in humans belongs to the Access group
- Total incidence of bloodstream infections with:
 - ✓ methicillin-resistant *Staphylococcus aureus* (MRSA) : to be reduced by 15% in the EU
 - ✓3rd generation cephalosporins-resistant *Escherichia coli*: to be reduced by 10% in the EU
 - ✓ carbapenem-resistant Klebsiella pneumoniae: to be reduced by 5% in the EU

Annex: recommended national targets to reach overall EU targets

F. Awareness, education and training

- National continuous education programmes and curricula
- Communication and awareness-raising
 - On collection and safe disposal of antimicrobials (professionals and public)
 - On **AMR** and **prudent use of antimicrobials** (professionals, public and specific population groups)
- Coordination (Member States, Commission, EU Agencies, other relevant bodies) to maximize impact
- Commission support to Member States

G. Research & development and incentives for innovation & access to antimicrobials and other AMR medical countermeasures

- Support of research and technological innovation
- **Development** of and **accessibility** to antimicrobials and other medical countermeasures
- Union multi-country pull incentive scheme to improve innovation, development and access to antimicrobials
 - Resources, collaborative actions, financial contribution
 - Regular review
 - Dedicated network
 - Development and placing on the market of alternatives to antimicrobials and vaccines for animal health

H. Cooperation

- Reporting to the Global Antimicrobial Resistance and Use Surveillance System (GLASS)
- Enhanced used of the EU AMR One Health Network
- Enhanced cooperation on AMR between professionals working in human health,
 veterinary and agronomy sectors and with stakeholders
- Cooperation on AMR between EFSA, EMA, ECDC, EEA and ECHA: interagency AMR working group
- Development of a **monitoring framework** to assess the progress and results achieved (2017 AMR Action Plan and Recommendation)

I. Global

- Development, and the implementation by third countries, of standards by the International Standard Setting Bodies
- Inclusion of concrete provisions on AMR in a potential WHO international agreement on pandemic prevention, preparedness and response
- **Support to WHO initiatives** (guidance on how GMPs should be implemented to waste and wastewater management for production of antimicrobials)
- AMR to feature as a high political priority in G7 and G20 settings
- Planned United Nations High Level conference on AMR in 2024 to raise global commitments
- Quadripartite's <u>AMR Multi-Stakeholder Partnership Platform</u>
- Development capacity and support in low-and-middle income countries